Previous 10 | Next 10 |
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U. S. Food and Drug Administration (FDA)...
WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and b...
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of ...
Futures are up over 0.4% in the pre-market sessions and it looks like it will be a bull’s day today. Futures on the Dow Jones Industrial Average gained 151 points, or 0.47%. S&P 500 futures rose 0.44% while Nasdaq 100 futures added 0.4%. Treasury Secretary Janet Yellen cautioned Tu...
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced results from a pivotal bioequivalence study comparing ...
McEwen Mining (MUX), Minerva Neurosciences (NERV), and American Resources Corporation (AREC) were recently downgraded in the POWR Ratings. Investors who own these stocks should reevaluate their positions as soon as possible. I Over the last two weeks, the market has been steadily moving l...
WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud’s retirement and transition...
Minerva Neurosciences, Inc. (NERV) Q2 2021 Results Conference Call August 2, 2021 8:30 AM ET Company Participants William Boni - Vice President, Investor Relations & Corporate Communications Remy Luthringer - Executive Chairman & Chief Executive Officer Geoff Race - Executive Vice Pre...
Minerva Neurosciences (NASDAQ:NERV): Q2 GAAP EPS of -$0.25 misses by $0.08. Cash, cash equivalents, restricted cash and marketable securities as of June 30, 2021 were approximately $74.3 million, compared to $25.5 million as of December 31, 2020. Press Release For further details see: M...
WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to ...